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(57) ABSTRACT 
A method for diagnosing and assessing a brain-related 
chronic pain disorder. The method includes assessing a Sub ject's brain function, determining the probability that a sub 
ject is Suffering from chronic pain as a result of an abnormal 
brain function condition by obtaining a quantitative assess 
ment of the Subject's brain function, and making a statistical 
comparison between the Subject's quantitative brain function 
assessment and either a database of quantitative assessments 
of the brain functions of normal, healthy individuals, or a 
database of quantitative assessments of the brain functions of 
individuals known to have been Suffering from chronic pain 
as a result of the abnormal brain function condition. 
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Figure 1 a 
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Figure 1b. 
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Figure 1c 
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Figure 1d 
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BRAIN-RELATED CHRONIC PAIN 
DISORDER DAGNOSS AND ASSESSMENT 
METHOD 
CROSS-REFERENCES TO RELATED 
APPLICATIONS 
0001. This application claims priority in U.S. Provisional 
Patent Application Ser. No. 61/014,917, filed Dec. 19, 2007. 
BACKGROUND OF THE INVENTION 
0002 1. Field of the Invention 
0003. This invention relates generally to a method for 
diagnosing and assessing brain-related chronic pain disorders 
in human Subjects. 
0004 2. Description of Related Art 
0005. Several methods of diagnosing and assessing fibro 
myalgia are known in the art. For example, U.S. Pat. No. 
5,834,215 issued 10 Nov. 1998 to Garry, et al. discloses a 
method of detecting antipolymer antibodies as a means of 
diagnosing fibromyalgia. U.S. Pat. No. 7,056,686 issued 6 
Jun. 2006 to Lin, et al., discloses a method for diagnosing 
fibromyalgia by detecting the presence of Small intestinal 
bacterial overgrowth. In addition, U.S. Pat. No. 7,146,205 
issued 5 Dec. 2006 to Holman teaches a diagnosis and treat 
ment method involving the use of inhibitors of sympathetic 
nervous system activities. However, none of these methods 
address the role of brain function in the pathology of fibro 
myalgia. 
0006. Also known in the art are methods for quantitatively 
analyzing analog electroencephalogram (EEG) signals. 
These methods are generally known as "quantitative electro 
encephalography', or qEEG, and are disclosed, for example, 
in U.S. Pat. No. 5,230,346 issued 27 Jul. 1993 to Leuchter, et 
al. and U.S. Pat. No. 6,097,980 issued 1 Aug. 2000 to Monas 
tra, et al. However, nothing in the prior art of record contem 
plates the use of qEEG analysis methods to diagnose or assess 
a brain-related chronic pain disorder Such as fibromyalgia. 
0007. In addition, the use of EEG and qEEG analyses in 
diagnosis, assessment, prognosis, and therapeutic activities is 
known in the art and disclosed, for example, in U.S. Pat. Nos. 
7,276,026 issued 2 Oct. 2007 to Skinner; U.S. Pat. No. 7, 177, 
675 issued 13 Feb. 2007 to Suffin, et al., U.S. Pat. No. 7,269, 
455 issued 11 Sep. 2007 to Pineda; U.S. Pat. No. 7,231.245 
issued 12 Jun. 2007 to Greenwald, et al.; U.S. Pat. No. 6,097, 
980 issued 20 Sep. 2005 to Gevins, et al; and U.S. Pat. No. 
6,947,790 issued 20 Sep. 2007 to Gevins, et al. However, 
none of the diagnostic and assessment methods disclosed in 
the 026, 675, 455, 245, 980, and 790 patents is able to 
diagnose or assess brain-related chronic pain disorders such 
as fibromyalgia. 
0008 What is needed is a method for diagnosing and 
assessing brain-related chronic pain disorders in human Sub jects by assessing brain function. 
BRIEF SUMMARY OF THE DISCLOSURE 
0009. A method is provided for diagnosing and assessing 
a brain-related chronic pain disorder. The method includes 
the steps of assessing a subject's brain function, determining 
the probability that a Subject is Suffering from chronic pain as 
a result of an abnormal brain function condition by obtaining 
a quantitative assessment of the Subject's brain function, and 
making a statistical comparison between the Subject's quan 
titative brain function assessment and either a database of 
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quantitative assessments of the brain functions of normal, 
healthy individuals, or a database of quantitative assessments 
of the brain functions of individuals known to have been 
Suffering from chronic pain as a result of the abnormal brain 
function condition. 
BRIEF DESCRIPTION OF THE DRAWINGS 
0010. These and other features and advantages of the 
invention will become apparent to those skilled in the art in 
connection with the following detailed description and draw 
ings, in which: 
0011 FIG. 1A is a flow chart depicting a method per 
formed according to the invention; 
0012 FIG. 1B is a continuation of the flow chart of FIG. 
1A: 
0013 FIG. 1C is a continuation of the flow chart of FIG. 
1B: 
0014 FIG. 1D is a continuation of the flow chart of FIG. 
1C.; and 
0015 FIG. 1E is a continuation of the flow chart of FIG. 
1D. 
DETAILED DESCRIPTION OF INVENTION 
EMBODIMENT(S) 
0016 A method is provided for diagnosing and assessing 
a brain-related chronic pain disorder. The method includes 
assessing a human Subject's brain function and then deter 
mining the probability that the subject is suffering from 
chronic pain related to an abnormal brain function condition 
by obtaining a quantitative assessment of the Subject's brain 
function and making a statistical comparison between the 
Subject's quantitative brain function assessment and a data 
base of quantitative assessments of the brain functions of 
individuals known to have been Suffering from chronic pain 
as a result of the abnormal brain function condition. The 
assessment of a Subject's brain function may include obtain 
ing an electroencephalogram (EEG) of the Subject's electrical 
brain activity, and the determination of the probability that the 
Subject is suffering from chronic pain as a result of an abnor 
mal brain function condition may include determining the 
probability that the subject is suffering from a chronic pain 
condition Such as fibromyalgia by obtaining a quantitative 
assessment of the Subject's EEG (dEEG) and making a sta 
tistical comparison between the subject's qEEG and a data 
base of qBEGs of individuals known to have been suffering 
from fibromyalgia. 
0017. A physical assessment may first be performed of a 
human Subject presenting with a complaint of symptoms 
characteristic of a chronic pain condition Such as fibromyal 
gia. The physical assessment may include, among other 
things, a determination of chronic widespread pain, sleep 
difficulty, fatigue, morning stiffness of the muscles and joints, 
cognitive difficulty and other symptoms associated with the 
condition. Where, for example, fibromyalgia is suspected, the 
physical assessment may also include tests performed to 
exclude various non-fibromyalgia conditions as the cause of 
the symptoms. Such further testing may include palpation of 
18 tender points in the manner prescribed by the American 
College of Rheumatology (ACR), with Such palpation being 
performed to determine whether the subject has an abnormal 
sensitivity to pain. Where, for example, idiopathic chronic 
low back pain ICLBP) is suspected, the physical assessment 
may include tests performed to exclude various non-ICLBP 
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conditions as the cause of the symptoms. Such further testing 
may include palpation of tender points other than the 18 
tender points prescribed by the ACR and/or may include 
physical tests other than tender point palpation. 
0018. In the absence of a definitive diagnosis, an EEG test 
may be performed in addition to the physical assessment. 
Specifically, the subject may be made comfortable by, for 
example, being seated or reclined. Preparation of the scalp in 
accordance with commonly followed procedures for per 
forming a clinical EEG may be done by a person of sufficient 
competence. EEG electrodes may then be adapted to be worn 
on the scalp, preferably in Scalp locations identified as the 
“International 10-20” standard sites, using common methods 
of affixing the electrodes such that they rest on or otherwise 
contact tissues. 
0019 While any number of electrodes may be used, a 
preferred number is either 19 or 24, in accordance with the 
number of electrode sites used to construct various indepen 
dent databases utilized to represent the EEG of a healthy 
normal population. 
0020 Records of the subject's EEG from each electrode 
site may then acquired under the conditions of both their eyes 
being closed and their eyes being open, with each condition 
producing a separate data record. In other words, an “eyes 
open EEG record may be obtained, which includes EEG data 
obtained from each electrode site while the subject's eyes are 
open and an “eyes closed EEG record may be obtained, 
which includes EEG data obtained from each electrode site 
while the subject's eyes are closed. Preferably, a minimum of 
five minutes of EEG data may be obtained from each elec 
trode site for each "eyes open EEG record and a minimum of 
five minutes of EEG data may be obtained from each elec 
trode site for each "eyes closed EEG record to assure that 
enough EEG data is recorded to produce statistically signifi 
cant samples from each electrode site, both with the subject's 
eyes open and with the subject's eyes closed. This is further 
described below. 
0021 Preferably, an additional test may be performed in 
which at least one additional EEG record is made that 
includes EEG data obtained at each electrode site while pain 
is elicited in the Subject. In diagnosing or assessing conditions 
Such as fibromyalgia, a number of tender points on the Sub ject's body may be palpated. In this test, henceforth referred 
to as a “tender point palpation (TPP) test”, a number of tender 
points on the Subject's body, preferably ranging between one 
and 18 when diagnosing or assessing fibromyalgia, are iden 
tified and serially palpated, preferably with an algometer. 
Preferably, four tender points may be chosen, and, preferably, 
those four points include tender points adjacent the right and 
left lateral epicondyle of the arms, and tender points adjacent 
the right and left costochondral junctions of the second rib. 
While the subject's eyes are preferably closed during this test, 
it should not be confused with the “eyes closed’ test described 
above. 
0022. The TPP test may be executed by acquiring an EEG 
record (“TPP” EEG record) including EEG data obtained 
from the electrode sites for a first tender point by first com 
mencing the acquisition of EEG data and then, a short period 
of time later, commencing palpation of the first tender point. 
Preferably, the period of time between the commencement of 
data acquisition and the commencement of palpation of the 
first tender point may be between one and three hundred 
seconds. Palpation of the first tender point may be accom 
plished by pressing on the tender point with an algometer, 
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preferably at a rate of approximately one kilogram per centi 
meter squared per second, until the Subject reports a painful 
sensation. Preferably, palpation pressure may be removed as 
Soon as the Subject reports a painful sensation. A record is 
made of the amount of the pressure being applied at the 
moment the Subject reports a painful sensation. Although the 
TPPEEG record may be obtained while the subject's eyes are 
closed, it should not be confused with the “eyes closed EEG 
record described above. 
0023. Further according to the TPP test method, the acqui 
sition of the TPP EEG record may include continued record 
ing of EEG data (with the subject's eyes closed) for a period 
of time after release of palpation pressure, preferably between 
1 and 300 seconds, and most preferably, for at least 60 sec 
onds. A comparison may then be made between EEG data 
collected before application of palpation pressure and EEG 
data collected after release of palpation pressure. This com 
parison may then be used to make diagnostic findings. Such 
findings may include changes in brain EEG activity, when 
comparing EEG after release of palpation pressure to EEG 
before palpation pressure, in specific regions of the brain 
characteristic of a brain-related chronic pain condition, but 
not otherwise anticipated in a healthy normal individual. 
0024. Following this period, a second and subsequent ten 
der point may be serially palpated, preferably with an algo 
meter, in the same manner as described for the first, with TPP 
EEG records being recorded for each by recording the eyes 
closed EEG for each site in the manner described with regard 
to obtaining the TPPEEG record for the first site. This process 
may be repeated for each chosen tender point. Accordingly, 
the resulting EEG data record includes the TPP EEG records 
acquired for each chosen tender point. 
(0025. The “TPP” EEG records may be acquired for a 
period of time that is sufficient to extract from each “TPP 
EEG record a minimum of 60 seconds of “clean EEG data, 
that is, data free of extraneous electrical noise Such as that 
from electromyographic movement. Preferably, all EEG 
records (“eyes open EEG records, “eyes closed EEG 
records, and “TPP” EEG records) may be individually edited 
to provide from each EEG record a minimum of 60 seconds of 
clean EEG. Preferably, the clean data is obtained so as to 
present a high degree of statistical consistency. Such mea 
sures as “Split-Half reliability, which is the ratio of variance 
between the even and odd seconds of the time series of 
selected clean EEG, and “Test Re-test” reliability, which is 
the ratio of variance between the first half and the second half 
of the selected clean EEG segments may be used. Preferably, 
clean EEG data is obtained such that measures of these ratios 
are a minimum of 0.95 and 0.90 respectively, which is con 
sistent with levels of reliability commonly published in EEG 
literature. 
(0026. With regard to the TPP test method, clean data 
includes that EEG data acquired after palpation of a tender 
point, and does not include any EEG data acquired during the 
palpation of a tender point. In addition, to assess the stability 
of a TPP EEG record, EEG data acquired before palpation of 
a tender point may be removed, edited and Statistically com 
pared to like data in the “eyes closed EEG record obtained 
from the eyes closed EEG test. Stability of the “closed eyes’ 
and TPPEEG records is indicated by a finding that there is no 
statistically significant difference between the “eyes closed 
EEG record and the pre-palpation portion of the. TPP EEG 
record. A contrary finding indicates instability and a need to 
repeat the EEG tests. 
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0027. Further to the method, and in the preferred embodi 
ment, clean “eyes open”, “eyes closed”, and “PPT EEG 
records may be then mathematically analyzed for various 
time domain and frequency domain parameters of their 
respective electrical signals. These analyses may include, but 
are not limited to Voltage and current analyses, frequency 
spectrum analyses using methods such as a Fast Fourier 
Transform or wavelet analysis, an absolute power analysis, a 
relative power analysis, a phase analysis, a coherence analy 
sis, an amplitude asymmetry analysis, and localization of 
electrical activity in the brain using inverse EEG computation 
analysis. 
0028 Findings from the aforementioned analyses may 
then be statistically compared to the same parameters deter 
mined from “eyes open”, “eyes closed”, and “PPT EEG 
records taken from an age and gender matched database of 
healthy normal individuals. Such statistical analyses may 
include, but are not limited to deviations from a standard 
normal distribution. Findings of Statistically significant 
abnormal deviation, or lack thereof, may then be presented in 
a graphical or numerical format for analysis by a competent 
health care professional or person of similar expertise. 
0029 EEG abnormalities consistent with those observed 
in a sample population of fibromyalgia patients may include, 
but are not limited to one or more of the following: (1) an 
overall reduction in EEG power across all spectra in either of 
the eyes open or eyes closed conditions; (2) statistically sig 
nificant low EEG power levels in frontal or temporal regions 
of any of the delta (1-3.5 hertz), theta (4-7.5 hertz) or alpha 
(8-12 hertz) frequency segments of EEG for the eyes closed 
condition; (3) statistically significant low coherence among 
the frontal EEG sites for the delta or theta EEG segments in 
either of the eyes closed or eyes open conditions; (4) statisti 
cally significant high relative beta (12.5-25 hertz) absolute 
power in the parietal region of the brain for either of the eyes 
closed or eyes open conditions. The magnitude of statistical 
variation considered to be statistically "significant may vary 
depending on the application. For example, in research, a 
difference between a sample and a population measure gen 
erally has to have a p-value of 0.01 or less for the difference to 
be considered statistically “significant'. However, in clinical 
application statistically significant differences may be 
declared with p-values at the 0.1 level or less. 
0030. Further EEG abnormalities consistent with those 
observed in a sample population offibromyalgia patients, and 
drawn particularly to the TPP test method, may include but 
are not limited to a finding of (1) a statistically significant 
increase in EEG absolute power, particularly in the alpha and 
beta segments, in the parietal and occipital areas of the brain 
as compared to the “eyes closed EEG record (“eyes closed 
EEG findings without tender point palpation) for the same 
Subject; or (2) a statistically significant increase in coherence 
in the alpha or beta segment of EEG. 
0031. A diagnosis of fibromyalgia may be made when 
physical assessment findings that Support a diagnosis of 
fibromyalgia are augmented by (1) at least one abnormal 
finding resulting from the TPP test, preferably a finding of a 
statistically significant increase in EEG absolute power, and 
particularly in the alpha and beta segments, in the parietal and 
occipital areas of the brain as compared to the eyes closed 
findings without tender point palpation for the same subject; 
and preferably (2) at least one abnormal finding resulting 
from the eyes closed EEG test, preferably statistically signifi 
cant low EEG power levels in frontal or temporal regions of 
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any of the delta, theta or alpha frequency segments of EEG for 
the eyes closed condition, and most preferably with an addi 
tional finding of statistically significantlow coherence among 
the frontal EEG sites for the delta or theta EEG segments. 
0032 Clean EEG records from a subject may be math 
ematically analyzed for various time domain and frequency 
domain parameters of their electrical signals, consistent with 
analysis techniques already described, and then findings from 
these mathematical analyses may be statistically compared to 
like parameters taken from an age and gender matched data 
base of individuals known to have fibromyalgia. The statisti 
cal comparisons may include, but are not limited to deviations 
from a standard normal distribution of like EEG measures 
associated with members of a database of individuals known 
to have fibromyalgia. The results of those comparisons may 
then be presented in a graphical or numerical format for 
analysis by a competent health care professional or person of 
similar expertise for the existence of Statistically significant 
abnormal deviations, or the lack thereof. A finding in Support 
of a fibromyalgia diagnosis would be supported if there is an 
absence of any significant deviation between measures from 
a subject's clean EEG and those from a database comprising 
individuals known to have fibromyalgia. 
0033 Similarly, clean EEG from a subject may be math 
ematically analyzed for various time domain and frequency 
domain parameters of its electrical signals, consistent with 
analysis techniques already described, and then findings from 
these mathematical analyses may be statistically compared to 
like parameters determined from an age and gender matched 
database of individuals known to have a chronic pain condi 
tion other than fibromyalgia. 
0034. The statistical comparisons may include, but are not 
limited to deviations from a standard normal distribution of 
like EEG measures associated with members of a database of 
individuals known to have the chronic pain condition. The 
results of those comparisons may then be presented in a 
graphical or numerical format for analysis by a competent 
health care professional or person of similar expertise for the 
existence of statistically significant abnormal deviations, or 
the lack thereof. A finding in Support of a chronic pain con 
dition diagnosis would be supported if there is an absence of 
any significant deviation between measures from a subject's 
clean EEG and those from a database comprising individuals 
known to have the chronic pain condition. 
0035) To determine the probability that a subject belongs 
to a population of individuals Suffering from fibromyalgia a 
statistical comparison may be made of EEG parameters of the 
Subject, as determined from the aforementioned analyses, to 
like EEG parameters determined from a database of individu 
als known to suffer from fibromyalgia. The statistical com 
parison may include, but is not limited to, determination of 
Z-Statistics associated with specific EEG measures from a 
standard normal distribution determined from the database of 
individuals known to suffer from fibromyalgia. Probability of 
inclusion in the population of individuals Suffering from 
fibromyalgia would result from findings that Subject mea 
Sures cannot be excluded from the database standard normal 
distribution. Assuming that the data in the database of fibro 
myalgia patient EEG is normally distributed, then statistics 
Such as the t-statistic or the Z-Statistic can be used to deter 
mine the probability that the sample EEG belongs to the 
population of fibromyalgia sufferers. If the probability is 
sufficiently low (e.g. p-0.01) then a conclusion could be 
made that the sample does not belong to that population. 
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0036 Similarly, the probability that a subject belongs to 
the population of individuals suffering from a chronic pain 
condition other than fibromyalgia may be determined by 
making statistical comparison of EEG parameters of a Sub 
ject, determined from the aforementioned analyses, to like 
EEG parameters determined from a database of individuals 
known to suffer from that chronic pain condition. The statis 
tical comparison may include, but is not limited to, determi 
nation of Z-statistics associated with specific EEG measures 
from a standard normal distribution determined from the 
database of individuals known to suffer from the chronic pain 
condition. Probability of inclusion in the population of indi 
viduals Suffering from the chronic pain condition other than 
fibromyalgia would result from findings that Subject mea 
Sures cannot be excluded from the database standard normal 
distribution. 
0037. In addition, findings from aforementioned analyses 
of clean EEG records from a subject may be statistically 
correlated to measures of symptom severity. As previously 
described, analysis findings may be mathematically analyzed 
for various time domain and frequency domain parameters of 
their electrical signals. A number of measures of the magni 
tude of deviation from standard normal distributions of either 
healthy normal EEG, known fibromyalgia patient EEG, or 
from EEG of individuals known to suffer from a chronic pain 
condition other than fibromyalgia can be determined. The 
magnitudes are presumed to be related to the severity of the 
condition, and may be statistically correlated to Such symp 
tom measures that may include, but are not limited to tender 
point pain pressure thresholds as determined by an algometer, 
and various other indices of pain derived from the algometry 
measures (e.g. the sum of all 18 tender point pain tolerance 
measures, the average of all 18 tender point pain tolerance 
measures, etc.). Such analysis has utility in both predicting 
symptom severity in individuals with fibromyalgia, and in 
determining the effect of therapeutic intervention to corrector 
manage symptoms of fibromyalgia. 
0038 Also the above-described EEG testing and statisti 
cal analysis methods may be repeated on a subject following 
a period of therapeutic intervention on the subject. The results 
of these statistical analyses may be statistically compared to 
like statistical analyses of the subject accomplished before 
therapeutic intervention was started. This comparison might 
include, but is not be limited to, paired t-testing statistics, 
correlation analysis of changes in Symptom severity, and 
Subsequent comparison to a database of age and gender 
matched healthy normal individuals. The comparisons could 
be used as a means of assessing the effectiveness of a chosen 
therapeutic intervention, or as a means of determining if an 
alternate intervention may be indicated in the absence of 
treatment effect from a current therapeutic intervention. The 
comparisons could also be used as a means of determining if 
further therapeutic intervention may be indicated in the 
absence of any abnormal findings. With regard to the TPP test, 
repeat testing may include applying tender point pressure 
with an algometer only to the levels required to cause a 
painful response recorded in the same testing performed 
before therapeutic intervention. 
0039 EEG data may be acquired from a subject at a first 
location (e.g. a clinical location) and the EEG data may be 
transferred via electronic means to another location (e.g. a 
central analysis location) for the herein described analysis 
and statistical comparisons. The electronic means of data 
transfer may include, but is not be limited to, data transfer 
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across a local area network or the internet. Analyses and 
statistical findings may then be transferred from the central 
analysis location to the clinical location where they can be 
used in various ways by a physician or similarly qualified 
health care professional for the determination of best clinical 
practice and therapeutic intervention. 
0040 EEG data may also be acquired from a subject at a 
first location (e.g. a clinical location) and the EEG data trans 
ferred via electronic means to another location (e.g. a central 
analysis location) for the purpose of increasing the size of 
various databases of individuals known to be suffering from 
fibromyalgia, individuals known to be suffering from a 
chronic pain condition other than fibromyalgia, and/or 
healthy normal individuals. 
0041. In testing for chronic pain conditions other than 
fibromyalgia, other, more general physical tests may be per 
formed. Some of those tests may include a form of tender 
point palpation that differs from that typically done in testing 
for fibromyalgia, and that differs in a way that makes the 
testing more useful in diagnosing other chronic pain condi 
tions. For example, tests involving algometer palpation may 
be performed at several points on the body of a suspected 
ICLBP patient, but not necessarily at the same 18 tender 
points described above for diagnosing and/or assessing fibro 
myalgia. Testing for ICLBP may include some other form of 
tender point palpation including physical action that causes 
reproduction of the back pain. Just as in the method disclosed 
for diagnosing and/or assessing fibromyalgia, this general 
physical test may be done following a period of EEG collec 
tion, and then additional EEG data may be captured after the 
test. Further, just as in the method disclosed for diagnosing 
and/or assessing fibromyalgia, differences in the EEG data 
may then be analyzed and/or statistically compared to deter 
mine if the result belongs to a particular chronic pain condi 
tion such as ICLBP. For example, the ideal test for an ICLBP 
patient might include palpation of four FM tender points and 
performance of a number of other physical actions that cause 
reproduction of pain specific to ICLBP patients. If the EEG 
analysis then shows a negative finding for the fibromyalgia 
tender points but a positive finding for the back pain actions, 
then a conclusion that the patient has ICLBP would be sup 
ported rather than a conclusion that the patient is Suffering 
from fibromyalgia. 
0042. This description, rather than describing limitations 
of an invention, only illustrates embodiments of the invention 
to be recited in the claims. The language of this description is 
therefore exclusively descriptive and is non-limiting. Obvi 
ously, it's possible to modify this invention from what the 
description teaches. One may practice the invention other 
than as described above. 
1. A method for diagnosing and assessing a brain-related 
chronic pain disorder, the method including the steps of 
assessing a subject's brain function; 
determining the probability that a subject is suffering from 
chronic pain as a result of an abnormal brain function 
condition by obtaining a quantitative assessment of the 
Subject's brain function; and 
making a statistical comparison between the Subject's 
quantitative brain function assessment and either: 
a database of quantitative assessments of the brain func 
tions of normal, healthy individuals, or 
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a database of quantitative assessments of the brain func 
tions of individuals known to have been suffering 
from chronic pain as a result of the abnormal brain 
function condition. 
2. The method of claim 1 in which: 
the step of assessing a Subject's brain function includes 
obtaining an electroencephalogram (EEG) of the Sub 
ject's electrical brain activity; and 
the step of determining the probability includes determin 
ing the probability that the subject is suffering from the 
abnormal brain function condition by: 
obtaining a quantitative assessment of the Subject's EEG 
(qEEG), and 
making a statistical comparison between the Subject's 
qEEG and either: 
a database of qEEGs of normal, healthy individuals, 
O 
a database of qBEGs of individuals known to have 
been suffering from the abnormal brain function 
condition. 
3. The method of claim 2 in which: 
the step of assessing a Subject's brain function includes 
obtaining an electroencephalogram (EEG) of the Sub 
ject's electrical brain activity; 
the step of determining the probability that a subject is 
Suffering from chronic pain as a result of abnormal brain 
function includes: 
obtaining a quantitative assessment of the Subject's EEG 
(qEEG), and 
making a statistical comparison between the Subject's 
qEEG and a database of qEEGs of individuals known 
to have been Suffering from chronic pain as a result of 
abnormal brain function; and 
the step of determining the probability that the subject is 
Suffering from chronic pain as a result of the abnormal 
brain function condition includes making a statistical 
comparison between the subject’s qEEG and a database 
of qBEGs of the brain functions of individuals known to 
have been suffering from the abnormal brain function 
condition. 
4. (canceled) 
5. (canceled) 
6. The method of claim 2 in which the step of assessing a 
subject's brain function includes obtaining a “TPP EEG' 
record of EEG data obtained over a period of time during 
which at least one tender point on the subject's body is pal 
pated. 
7. The method of claim 6 in which an algometer is used to 
palpate at least one tender point on the subject's body while 
the “TPP EEG record is being obtained. 
8. The method of claim 6 in which: 
the step of making a statistical comparison includes mak 
ing Such a comparison between the Subject's qEEG and 
a database of qBEGs of individuals known to have been 
Suffering from fibromyalgia; and 
the step of palpating at least one tender point includes 
serially palpating the right and left lateral epicondyle of 
the arms, and the right and left costochondral junctions 
of the second rib. 
9. (canceled) 
10. The method of claim 6 in which the step of palpation at 
least one tender point includes increasing pressure on the 
tender point with an algometer until the Subject reports a 
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painful sensation, and recording the amount of pressure being 
applied at the moment the Subject reports a painful sensation. 
11. (canceled) 
12. (canceled) 
13. (canceled) 
14. The method of claim 6 in which the palpation and 
recording steps are repeated for each tender point. 
15. (canceled) 
16. (canceled) 
17. (canceled) 
18. The method of claim 6 in which: 
the step of obtaining an EEG includes: 
acquiring an “eyes closed EEG record of data obtained 
while the subject's eyes are closed for a period of time 
Sufficient to obtain statistically significant sample; 
and 
acquiring an “eyes open’ EEG record of data obtained 
while the subject's eyes are open for a period of time 
Sufficient to obtain statistically significant sample; 
and 
the step of obtaining a “TPPEEG recordincludes deter 
mining stability of the EEG by comparing pre-palpa 
tion EEG data with EEG data obtained from the “eyes 
closed EEG record, and repeating the step of obtain 
ing an EEG if there is a statistically significant differ 
ence between the pre-palpation EEG data of the “TPP 
EEG record and the EEG data of the “eyes closed” 
EEG record. 
19. The method of claim 1 in which the step of assessing a 
Subject's brainfunction includes obtaining information on the 
Subject's brain using positron-emission tomography (PET), 
magnetic resonance imaging (MRI), or single photon emis 
sion computed tomography (SPECT). 
20. (canceled) 
21. (canceled) 
22. The method of claim 1 in which: 
the step of assessing a subject's brain function includes 
obtaining an electroencephalogram (EEG) of the Sub 
ject's electrical brain activity; and 
the step of obtaining a quantitative assessment includes 
obtaining one or more qBEG parameters by mathemati 
cally analyzing the Subject's EEG using one or more 
qEEG methods selected from the group consisting of 
Voltage analysis, current analysis, Voltage and current 
analysis, frequency spectrum analysis using Fast Fourier 
transform analysis, frequency spectrum analysis using a 
wavelet analysis method, frequency spectrum analysis 
using absolute power analysis method, frequency spec 
trum analysis using relative power analysis method, fre 
quency spectrum analysis using phase analysis method, 
frequency spectrum analysis using coherence analysis 
method, frequency spectrum analysis using amplitude 
symmetry analysis method, and localization of electrical 
activity in the brain using inverse EEG computation 
analysis. 
23. The method of claim 22 in which a particular abnormal 
brain function condition is diagnosed as a factor related to 
Subject's chronic pain by: 
detecting one or more deviations in a statistical comparison 
of the subject's one or more qBEG parameters to like 
qEEG parameters obtained from at least one healthy 
normal individual; and 
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comparing the one or more deviations to deviations 
detected in individuals known to have been suffering 
from the abnormal condition. 
24. (canceled) 
25. (canceled) 
26. The method of claim 1 in which the step of making a 
statistical comparison includes determining statistics associ 
ated with at least one EEG parameter from a standard normal 
distribution of like parameters in a database of individuals 
known to have been Suffering from an abnormal brain func 
tion condition causing chronic pain. 
27. (canceled) 
28. (canceled) 
29. (canceled) 
30. (canceled) 
31. (canceled) 
32. The method of claim 28 in which the abnormal brain 
function condition being diagnosed is fibromyalgia: 
the step of assessing a Subject's brain function includes 
obtaining a “TPP EEG record of EEG data obtained 
over a period of time during which at least one tender 
point on the Subject's body is palpated; and 
the deviation detected in a sample population of known 
fibromyalgia patents may include any one or more of the 
deviations included in the group of deviations consisting 
of a statistically significantly higher EEG absolute 
power values in the “TPP EEG records taken in the 
parietal and occipital areas of the brain as compared to 
the “eyes closed EEG records taken in the parietal and 
occipital areas of the brain of the same Subject; and a 
statistically significant increase in coherence in the 
alpha or beta segment of the “TPP EEG record. 
33. (canceled) 
34. (canceled) 
35. (canceled) 
36. (canceled) 
37. (canceled) 
38. (canceled) 
39. The method of claim 2 including the additional step of 
providing evidence of treatment effect on the abnormal brain 
function condition by performing EEG measures and qEEG 
analyses on a subject Suffering from the abnormal brain func 
tion condition following a period of therapeutic intervention 
on the Subject and making a statistical comparison to like data 
obtained before therapeutic intervention. 
Jun. 30, 2011 
40. (canceled) 
41. The method of claim 1 in which the comparison is used 
to assess the effectiveness of a chosen therapeutic interven 
tion, to determine whether an alternate intervention is indi 
cated, and/or to determine whether further therapeutic inter 
vention is indicated. 
42. The method of claim 2 in which: 
the step of assessing a subject's brain function includes 
obtaining a “TPP EEG record of EEG data obtained 
over a period of time during which at least one tender 
point on the Subject's body is palpated; and 
the EEG measures and qEEG analyses include obtaining 
and comparing “TPP EEG records from both before 
and after therapeutic intervention. 
43. (canceled) 
44. The method of claim 2 including the additional step of 
predicting symptom severity associated with the abnormal 
brain function condition by correlating at least one qBEG 
measure of symptom severity in a subject Suffering from the 
abnormal brain function condition to like qEEG measures of 
symptom severity in a group of individuals known to be 
suffering from the abnormal brain function condition. 
45. (canceled) 
46. The method of claim 44 in which the at least one qBEG 
measure of symptom severity includes the magnitude of 
deviation from a standard normal distribution of like qBEG 
measures from a database of Such measures taken from nor 
mal, healthy individuals. 
47. (canceled) 
48. (canceled) 
49. (canceled) 
50. (canceled) 
51. (canceled) 
52. The method of claim3 in which the step of determining 
the probability that the subject is suffering from chronic pain 
as a result of the abnormal brain function condition includes 
making a statistical comparison between the Subject’s qBEG 
and a database of qEEGs of the brain functions of individuals 
known to have been Suffering from one or more abnormal 
brain function conditions selected from the group of Such 
conditions consisting offibromyalgia, chronic back pain, and 
chronic headache. 
